Source-grounded facts extracted from BIODESIX INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BIODESIX INC reported the first quarter ended March 31, 2026 results: revenue $25.6 million, net income Net loss of $7.8 million. Guidance raised.
“Biodesix Announces First Quarter 2026 Results and Highlights Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 million”
BIODESIX INC: Filed a Certificate of Elimination to remove provisions related to Series A Non-Voting Convertible Preferred Stock (effective 2025-09-12).
“On September 12, 2025, Company filed a Certificate of Elimination of the Series A Non-Voting Convertible Preferred Stock (the “Certificate of Elimination”) with the Delaware Secretary of State effecting the elimination of all provisions of the Certificate of Designations previously filed by the Company with the Delaware Secretary of State on April 8, 2024 related to a series of preferred stock designated as Series A Non-Voting Convertible Preferred Stock.”
BIODESIX INC: Effected a one-for-twenty reverse stock split via amendment to the charter (effective 2025-09-15).
“Following such approval, the Company filed an amendment to its Charter (the “Reverse Split Amendment”) with the Secretary of State of the State of Delaware (the “Delaware Secretary of State”) to effect the Reverse Stock Split, with an effective time of 12:01 a.m. Eastern Time on September 15, 2025.”
Charles Watts, M.D. resigned as Director at BIODESIX INC.
“On April 15, 2025, Charles Watts, M.D., a member of the Board of Directors (the “Board”) of Biodesix, Inc. (the “Company”), notified the Company of his intention to resign from his position as a director of the Board and as a member of the Compensation Committee, effective at the conclusion of the Company’s 2025 Annual Meeting of Stockholders on May 20, 2025.”
BIODESIX INC reported the first quarter ended March 31, 2024 results: revenue $14.8 million, net income $13.6 million. Guidance reaffirmed.
“Total revenue of $14.8 million, an increase of 64%”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.